These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1335 related articles for article (PubMed ID: 32184360)
21. The Evolving Role of Bruton's Tyrosine Kinase Inhibitors in B Cell Lymphomas. Mehra S; Nicholls M; Taylor J Int J Mol Sci; 2024 Jul; 25(14):. PubMed ID: 39062757 [TBL] [Abstract][Full Text] [Related]
22. Destabilization of ROR1 enhances activity of Ibrutinib against chronic lymphocytic leukemia in vivo. Liu Z; Liu J; Zhang T; Shi M; Chen X; Chen Y; Yu J Pharmacol Res; 2020 Jan; 151():104512. PubMed ID: 31726100 [TBL] [Abstract][Full Text] [Related]
23. BTK-independent regulation of calcium signalling downstream of the B-cell receptor in malignant B-cells. Arthur R; Wathen A; Lemm EA; Stevenson FK; Forconi F; Linley AJ; Steele AJ; Packham G; Valle-Argos B Cell Signal; 2022 Aug; 96():110358. PubMed ID: 35597428 [TBL] [Abstract][Full Text] [Related]
24. Bruton's agammaglobulinemia tyrosine kinase (Btk) regulates TPA‑induced breast cancer cell invasion via PLCγ2/PKCβ/NF‑κB/AP‑1‑dependent matrix metalloproteinase‑9 activation. Kim JM; Park J; Noh EM; Song HK; Kang SY; Jung SH; Kim JS; Park BH; Lee YR; Youn HJ Oncol Rep; 2021 May; 45(5):. PubMed ID: 33760219 [TBL] [Abstract][Full Text] [Related]
29. MCIR1: A patient-derived mantle cell lymphoma line for discovering new treatments for ibrutinib resistance. Wu X; Nowakowski KE; Abeykoon JP; Manske M; Stenson MJ; Timm MM; Hanson CA; Van Dyke DL; Dasari S; Witzig TE Eur J Haematol; 2021 Oct; 107(4):458-465. PubMed ID: 34214199 [TBL] [Abstract][Full Text] [Related]
30. The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia. Herman SEM; Montraveta A; Niemann CU; Mora-Jensen H; Gulrajani M; Krantz F; Mantel R; Smith LL; McClanahan F; Harrington BK; Colomer D; Covey T; Byrd JC; Izumi R; Kaptein A; Ulrich R; Johnson AJ; Lannutti BJ; Wiestner A; Woyach JA Clin Cancer Res; 2017 Jun; 23(11):2831-2841. PubMed ID: 27903679 [No Abstract] [Full Text] [Related]
31. PI3K/AKT confers intrinsic and acquired resistance to pirtobrutinib in chronic lymphocytic leukemia. Kong C; Wu M; Lu Q; Ke B; Xie J; Li A Leuk Res; 2024 Sep; 144():107548. PubMed ID: 39018782 [TBL] [Abstract][Full Text] [Related]
32. Zanubrutinib (BGB-3111), a Second-Generation Selective Covalent Inhibitor of Bruton's Tyrosine Kinase and Its Utility in Treating Chronic Lymphocytic Leukemia. Rhodes JM; Mato AR Drug Des Devel Ther; 2021; 15():919-926. PubMed ID: 33688166 [TBL] [Abstract][Full Text] [Related]
33. Expression of functional sphingosine-1 phosphate receptor-1 is reduced by B cell receptor signaling and increased by inhibition of PI3 kinase δ but not SYK or BTK in chronic lymphocytic leukemia cells. Till KJ; Pettitt AR; Slupsky JR J Immunol; 2015 Mar; 194(5):2439-46. PubMed ID: 25632006 [TBL] [Abstract][Full Text] [Related]
34. Mechanisms of resistance to BTK inhibitors in patients with chronic lymphocytic leukemia. Woyach JA Clin Adv Hematol Oncol; 2021 Jul; 19(7):436-438. PubMed ID: 34236341 [No Abstract] [Full Text] [Related]
35. Bruton's tyrosine kinase (BTK) inhibitors alter blood glucose and insulin in obese mice but reduce inflammation independent of BTK. Chan DY; Barra NG; Fang H; Rodrigues E-Lacerda R; Schertzer JD Am J Physiol Endocrinol Metab; 2024 Sep; 327(3):E271-E278. PubMed ID: 39017678 [TBL] [Abstract][Full Text] [Related]
38. TLR Signaling Is Activated in Lymph Node-Resident CLL Cells and Is Only Partially Inhibited by Ibrutinib. Dadashian EL; McAuley EM; Liu D; Shaffer AL; Young RM; Iyer JR; Kruhlak MJ; Staudt LM; Wiestner A; Herman SEM Cancer Res; 2019 Jan; 79(2):360-371. PubMed ID: 30498085 [TBL] [Abstract][Full Text] [Related]
39. Targeting Bruton's Tyrosine Kinase in CLL. Ahn IE; Brown JR Front Immunol; 2021; 12():687458. PubMed ID: 34248972 [TBL] [Abstract][Full Text] [Related]
40. Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL). Woyach JA; Bojnik E; Ruppert AS; Stefanovski MR; Goettl VM; Smucker KA; Smith LL; Dubovsky JA; Towns WH; MacMurray J; Harrington BK; Davis ME; Gobessi S; Laurenti L; Chang BY; Buggy JJ; Efremov DG; Byrd JC; Johnson AJ Blood; 2014 Feb; 123(8):1207-13. PubMed ID: 24311722 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]